Autolus Therapeutics (NASDAQ: AUTL) reported Q2 EPS of ($0.15), $0.08 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $45.69 million versus the consensus estimate of $30.08 million.

For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.